Targeting Epigenetic Modifications in Uveal Melanoma

Area of Science:

• Ophthalmology
• Oncology
• Genetics

Background:

• Uveal melanoma (UM) is the most common primary intraocular malignancy.
• Despite treatment, approximately 50% of UM patients develop metastatic disease.
• Current therapies for advanced UM offer limited efficacy.

Purpose of the Study:

• To review the role of epigenetic dysregulation in uveal melanoma.
• To explore novel therapeutic strategies targeting epigenetic alterations in UM.
• To highlight the potential of CRISPR-dCas9 technology in UM treatment.

Main Methods:

• Review of current literature on uveal melanoma epigenetics.
• Analysis of epigenetic mechanisms including DNA methylation and histone modifications.
• Evaluation of CRISPR-Cas9 applications in epigenetic editing.

Main Results:

• Epigenetic dysregulation, including aberrant DNA methylation and histone modifications, significantly contributes to UM initiation and progression.
• Emerging epigenetic drugs show potential for combination therapies.
• CRISPR-dCas9 technology enables precise manipulation of epigenetic marks for therapeutic targeting.

Conclusions:

• Targeting epigenetic alterations represents a promising avenue for novel uveal melanoma therapies.
• Combination therapies incorporating epigenetic drugs may improve patient outcomes.
• CRISPR-dCas9 offers a powerful tool for both discovery and therapeutic targeting of epigenetic drivers in UM.